Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.

Although the difference in median PFS did not reach statistical significance in the overall cohort (12.7 vs. 8.0 months; Log-rank P = 0.242), stratifying by TKI generation revealed that non-CLFA patients treated with third-generation EGFR-TKIs achieved significantly better PFS (13.2 vs. 8.0 months, Log-rank P = 0.005) and OS (48.4 vs. 19.9 months, Log-rank P < 0.001) compared to their CLFA counterparts (Fig. 2 D–F).

also in 111,027 other papers